Andréane Lalonde

Andréane Lalonde

Auto-generated profile, based on publicly available information

Andréane Lalonde

Montreal Clinical Research Institute (IRCM), Montréal, Québec, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
IEIslam Elkholi
Islam Elkholi
ALAndréane Lalonde
Andréane Lalonde
MPMorag Park
Morag Park
JCJean-François Côté
Jean-François Côté
Multiple factors act in concert to define the fate of disseminated tumor cells (DTC) to enter dormancy or develop overt metastases. Here, we review these factors in the context of three stages of the metastatic cascade that impact DTCs. First, cells can be programmed within the primary tumor microenvironment to promote or inhibit dissemination, and the primary tumor can condition a premetastatic niche. Then, cancer cells from the primary tumor spread through hematogenous and lymphatic routes, and the primary tumor sends cues systematically to regulate the fate of DTCs. Finally, DTCs home to their metastatic site, where they are influenced by various organ-specific aspects of the new microenvironment. We discuss these factors in the context of breast cancer, where about one-third of patients develop metastatic relapse. Finally, we discuss how the standard-of-care options for breast cancer might affect the fate of DTCs.

24 November 2025
Verified
Other
Open access
IEIslam Elkholi
Islam Elkholi
ALAndréane Lalonde
Andréane Lalonde
MPMorag Park
Morag Park
JCJean-François Côté
Jean-François Côté
Figure S1. Current experimental models to study breast cancer metastatic dormancy. (a) Different pairs of cell lines are used to study breast cancer dormancy in vitro. Both 4T07 and D2OR cells remain dormant in the secondary site after spontaneous metastasis. In contrast, 4T1 and D2A1, their corresponding counterparts, form overt metastases. (b) A simplistic representation of the in vitro 3D culture systems’ components as described in different studies. ECM-like components such as collagen and laminin among other factors (fibronectin, heparin, TGFB and others) have been included in different culture systems to recapitulate the native microenvironments. In addition, these culture systems include various cell types to be co-cultured with the cancer cells such as stromal and endothelial cells. These culture systems allowed studying the dormancy phase and the consequent switch to a proliferative state. (c) The transgenic MMTV-Neu mouse model has been leveraged to study breast cancer dormancy in vivo. This HER2+ subtype model develops spontaneous mammary tumors, and early DTCs can be detected in the lungs and the bone marrow during the early stages of tumorigenesis such as ADH and DCIS, around 9 weeks of age, hence before the invasive stage onset which is typically seen around 23-30 weeks of age. The endpoint stage is characterized by the detection of macrometastases. However, whether metastases originate from early or late DTCs or both is still an open question.

31 March 2023
Verified
Other
Open access
IEIslam Elkholi
Islam Elkholi
ALAndréane Lalonde
Andréane Lalonde
MPMorag Park
Morag Park
JCJean-François Côté
Jean-François Côté
Figure S1. Current experimental models to study breast cancer metastatic dormancy. (a) Different pairs of cell lines are used to study breast cancer dormancy in vitro. Both 4T07 and D2OR cells remain dormant in the secondary site after spontaneous metastasis. In contrast, 4T1 and D2A1, their corresponding counterparts, form overt metastases. (b) A simplistic representation of the in vitro 3D culture systems’ components as described in different studies. ECM-like components such as collagen and laminin among other factors (fibronectin, heparin, TGFB and others) have been included in different culture systems to recapitulate the native microenvironments. In addition, these culture systems include various cell types to be co-cultured with the cancer cells such as stromal and endothelial cells. These culture systems allowed studying the dormancy phase and the consequent switch to a proliferative state. (c) The transgenic MMTV-Neu mouse model has been leveraged to study breast cancer dormancy in vivo. This HER2+ subtype model develops spontaneous mammary tumors, and early DTCs can be detected in the lungs and the bone marrow during the early stages of tumorigenesis such as ADH and DCIS, around 9 weeks of age, hence before the invasive stage onset which is typically seen around 23-30 weeks of age. The endpoint stage is characterized by the detection of macrometastases. However, whether metastases originate from early or late DTCs or both is still an open question.

31 March 2023
Verified
Other
Open access
IEIslam Elkholi
Islam Elkholi
ALAndréane Lalonde
Andréane Lalonde
MPMorag Park
Morag Park
JCJean-François Côté
Jean-François Côté
Figure S1. Current experimental models to study breast cancer metastatic dormancy. (a) Different pairs of cell lines are used to study breast cancer dormancy in vitro. Both 4T07 and D2OR cells remain dormant in the secondary site after spontaneous metastasis. In contrast, 4T1 and D2A1, their corresponding counterparts, form overt metastases. (b) A simplistic representation of the in vitro 3D culture systems’ components as described in different studies. ECM-like components such as collagen and laminin among other factors (fibronectin, heparin, TGFB and others) have been included in different culture systems to recapitulate the native microenvironments. In addition, these culture systems include various cell types to be co-cultured with the cancer cells such as stromal and endothelial cells. These culture systems allowed studying the dormancy phase and the consequent switch to a proliferative state. (c) The transgenic MMTV-Neu mouse model has been leveraged to study breast cancer dormancy in vivo. This HER2+ subtype model develops spontaneous mammary tumors, and early DTCs can be detected in the lungs and the bone marrow during the early stages of tumorigenesis such as ADH and DCIS, around 9 weeks of age, hence before the invasive stage onset which is typically seen around 23-30 weeks of age. The endpoint stage is characterized by the detection of macrometastases. However, whether metastases originate from early or late DTCs or both is still an open question.

31 March 2023
Verified
Other
Open access
IEIslam Elkholi
Islam Elkholi
ALAndréane Lalonde
Andréane Lalonde
MPMorag Park
Morag Park
JCJean-François Côté
Jean-François Côté
Multiple factors act in concert to define the fate of disseminated tumor cells (DTC) to enter dormancy or develop overt metastases. Here, we review these factors in the context of three stages of the metastatic cascade that impact DTCs. First, cells can be programmed within the primary tumor microenvironment to promote or inhibit dissemination, and the primary tumor can condition a premetastatic niche. Then, cancer cells from the primary tumor spread through hematogenous and lymphatic routes, and the primary tumor sends cues systematically to regulate the fate of DTCs. Finally, DTCs home to their metastatic site, where they are influenced by various organ-specific aspects of the new microenvironment. We discuss these factors in the context of breast cancer, where about one-third of patients develop metastatic relapse. Finally, we discuss how the standard-of-care options for breast cancer might affect the fate of DTCs.

31 March 2023
Verified
Other
Open access
IEIslam Elkholi
Islam Elkholi
ALAndréane Lalonde
Andréane Lalonde
MPMorag Park
Morag Park
JCJean-François Côté
Jean-François Côté
Multiple factors act in concert to define the fate of disseminated tumor cells (DTC) to enter dormancy or develop overt metastases. Here, we review these factors in the context of three stages of the metastatic cascade that impact DTCs. First, cells can be programmed within the primary tumor microenvironment to promote or inhibit dissemination, and the primary tumor can condition a premetastatic niche. Then, cancer cells from the primary tumor spread through hematogenous and lymphatic routes, and the primary tumor sends cues systematically to regulate the fate of DTCs. Finally, DTCs home to their metastatic site, where they are influenced by various organ-specific aspects of the new microenvironment. We discuss these factors in the context of breast cancer, where about one-third of patients develop metastatic relapse. Finally, we discuss how the standard-of-care options for breast cancer might affect the fate of DTCs.